Federated Hermes’s Terns Pharmaceuticals TERN Stock Holding History

Federated Hermes’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-719	Closed	-$37.9K	–	2182
2026 Q1	$37.9K	Buy	719 +550	+325%	+$22.6K	﹤0.01%	1708
2025 Q4	$6.83K	Buy	+169	New	+$3.91K	﹤0.01%	1866
2025 Q2	–	Sell	-225	Closed	-$621	–	2184
2025 Q1	$621	Sell	225 -558	-71%	-$2.28K	﹤0.01%	2017
2024 Q4	$4.34K	Buy	783 +300	+62%	+$2.03K	﹤0.01%	1909
2024 Q3	$4.03K	Sell	483 -733	-60%	-$6.03K	﹤0.01%	1876
2024 Q2	$8.28K	Buy	+1,216	New	+$7.37K	﹤0.01%	1797
2023 Q3	–	Sell	-168	Closed	-$1.47K	–	2196
2023 Q2	$1.47K	Buy	+168	New	+$1.96K	﹤0.01%	2010

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Federated Hermes's TERN Position: Q2 2026 in Review

Federated Hermes sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 719 shares — an estimated $37.9K sold.

Federated Hermes first reported a position in TERN in Q2 2023 and held it in 7 quarters. The position peaked at $37.9K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Federated Hermes reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Federated Hermes sold 719 Terns Pharmaceuticals shares in Q2 2026, an estimated $37.9K.
Federated Hermes first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 7 quarters.
Federated Hermes's Terns Pharmaceuticals position peaked at $37.9K in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.